|
1
|
American Cancer Society, . Cancer Facts
& Figures 2015. American Cancer Society; Atlanta, GA: 2015
|
|
2
|
Ries LAG, Young JL, Keel GE, Eisner MP,
Lin YD and Horner MJ: SEER Survival Monograph: Cancer Survival
Among Adults. U.S. Seer Program, 1988–2001, Patient And Tumor
Characteristics. National Cancer Institute, Seer Program, NIH Pub.
No. 07-6215; Bethesda, MD: 2007
|
|
3
|
Prat J; FIGO Committee on Gynecologic
Oncology, : Staging classification for cancer of the ovary,
fallopian tube and peritoneum. Int J Gynaecol Obstet. 124:1–5.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seiden MV: Gynecologic
malignanciesHarrison's Principles of Internal Medicine. Longo DL,
Kasper DL, Jameson JL, Fauci AS, Hauser SL and Loscalzo J: 1. 18th.
McGraw-Hill; New York, NY: pp. 810–816. 2012
|
|
5
|
Suh KS, Park SW, Castro A, Patel H, Blake
P, Liang M and Goy A: Ovarian cancer biomarkers for molecular
biosensors and translational medicine. Expert Rev Mol Diagn.
10:1069–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gupta D and Lis CG: Role of CA125 in
predicting ovarian cancer survival-a review of the epidemiological
literature. J Ovarian Res. 2:132009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ozols RF: The current role of gemcitabine
in ovarian cancer. Semin Oncol. 28 2 Suppl 7:S18–S24. 2001.
View Article : Google Scholar
|
|
8
|
Leon SA, Shapiro B, Sklaroff DM and Yaros
MJ: Free DNA in the serum of cancer patients and the effect of
therapy. Cancer Res. 37:646–650. 1977.PubMed/NCBI
|
|
9
|
Flamini E, Mercatali L, Nanni O, Calistri
D, Nunziatini R, Zoli W, Rosetti P, Gardini N, Lattuneddu A,
Verdecchia GM and Amadori D: Free DNA and carcinoembryonic antigen
serum levels: An important combination for diagnosis of colorectal
cancer. Clin Cancer Res. 12:6985–6988. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Silva JM, Dominguez G, Garcia JM, Gonzalez
R, Villanueva MJ, Navarro F, Provencio M, San Martin S, España P
and Bonilla F: Presence of tumor DNA in plasma of breast cancer
patients: Clinicopathological correlations. Cancer Res.
59:3251–3256. 1999.PubMed/NCBI
|
|
11
|
Gordian E, Ramachandran K, Reis IM,
Manoharan M, Soloway MS and Singal R: Serum free circulating DNA is
a useful biomarker to distinguish benign versus malignant prostate
disease. Cancer Epidemiol Biomarkers Prev. 19:1984–1991. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kamat AA, Bischoff FZ, Dang D, Baldwin MF,
Han LY, Lin YG, Merritt WM, Landen CN Jr, Lu C, Gershenson DM, et
al: Circulating cell-free DNA: A novel biomarker for response to
therapy in ovarian carcinoma. Cancer Biol Ther. 5:1369–1374. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mazurek AM, Fiszer-Kierzkowska A,
Rutkowski T, Składowski K, Pierzyna M, Scieglińska D, Woźniak G,
Głowacki G, Kawczyński R and Małusecka E: Optimization of
circulating cell-free DNA recovery for KRAS mutation and HPV
detection in plasma. Cancer Biomark. 13:385–394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ehrlich M, Gama-Sosa MA, Huang LH, Midgett
RM, Kuo KC, McCune RA and Gehrke C: Amount and distribution of
5-methylcytosine in human DNA from different types of tissues of
cells. Nucleic Acids Res. 10:2709–2721. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jabbari K and Bernardi G: Cytosine
methylation and CpG, TpG (CpA) and TpA frequencies. Gene.
333:143–149. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deaton AM and Bird A: CpG islands and the
regulation of transcription. Genes Dev. 25:1010–1022. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW,
Bang YJ and Kang GH: Methylation of RUNX3 in various types of human
cancers and premalignant stages of gastric carcinoma. Lab Invest.
84:479–484. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang S, Wei L, Zhang A, Zhang L and Yu H:
RUNX3 gene methylation in epithelial ovarian cancer tissues and
ovarian cancer cell lines. OMICS. 13:307–311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sierko E, Wojtukiewicz MZ and Kisiel W:
The role of tissue factor pathway inhibitor-2 in cancer biology.
Semin Thromb Hemost. 33:653–659. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sellar GC, Watt KP, Rabiasz GJ, Stronach
EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B,
Scott D, et al: OPCML at 11q25 is epigenetically inactivated and
has tumor-suppressor function in epithelial ovarian cancer. Nat
Genet. 34:337–343. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chuang LS and Ito Y: RUNX3 is
multifunctional in carcinogenesis of multiple solid tumors.
Oncogene. 29:2605–2615. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA. 93:pp.
9821–9826. 1996; View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li LC and Dahiya R: MethPrimer: Designing
primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ledermann JA, Raja FA, Fotopoulou C,
Gonzalez-Martin A, Colombo N and Sessa C; ESMO Guidelines Working
Group, : Newly diagnosed and relapsed epithelial ovarian carcinoma:
ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 24 Suppl 6:vi24–vi32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sung CK, Li D, Andrews E, Drapkin R and
Benjamin T: Promoter methylation of the SALL2 tumor suppressor gene
in ovarian cancers. Mol Oncol. 7:419–427. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Katsaros D, Cho W, Singal R, Fracchioli S,
De La Longrais IA Rigault, Arisio R, Massobrio M, Smith M, Zheng W,
Glass J and Yu H: Methylation of tumor suppressor gene p16 and
prognosis of epithelial ovarian cancer. Gynecol Oncol. 94:685–692.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ozdemir F, Altinisik J, Karateke A,
Coksuer H and Buyru N: Methylation of tumor suppressor genes in
ovarian cancer. Exp Ther Med. 4:1092–1096. 2012.PubMed/NCBI
|
